The phase 3 trial that put semaglutide on the map for liver disease reported its interim results at week 72, and the numbers are the strongest this drug class has produced outside weight and cardiovascular outcomes [1]. They also come attached to a dose and a duration, and that pairing is what a buyer on a price page has to fund.
What the trial found
Resolution of steatohepatitis without worsening fibrosis occurred in 62.9% of the 534 patients on semaglutide against 34.3% of the 266 on placebo, a difference of 28.7 percentage points (95% CI 21.1 to 36.2, P < 0.001). A reduction in fibrosis without worsening steatohepatitis came in at 36.8% against 22.4%, a difference of 14.4 points (95% CI 7.5 to 21.3). Both together reached 32.7% against 16.1%, a difference of 16.5 points (95% CI 10.2 to 22.8). Weight fell 10.5% against 2.0%. Gastrointestinal adverse events were more common on the drug.
The regimen is the cost
Every one of those figures belongs to once-weekly subcutaneous semaglutide at 2.4 mg. That is the top of the label ladder, not an opening dose. The trial runs 240 weeks in total and the results above are the interim read at 72.
So the question a price desk can answer is not whether the drug works on the liver. It is what 2.4 mg held for well over a year costs at the rates on this site — which is exactly what a flat-rate claim is worth checking against. Sellers who state their price holds at every dose are priced the same at 2.4 mg as at 0.25 mg; sellers who do not say are the ones whose bill is unknown at the dose this trial used. We count that split in what six months comes to, and the whole arithmetic sits in the cost calculator.
Two things the trial does not say
It does not say a compounded preparation at the same stated milligrams produces the same histology. Every patient here received the branded product under trial supply. And it does not say anyone should buy a GLP-1 to treat a liver they have not had biopsied — enrollment required biopsy-defined MASH with fibrosis stage 2 or 3, which is a diagnosis nobody gets from a telehealth intake. What a buyer can act on is duller: whether the seller they choose has published what happens to the price on the way up, a gap we count across the market in the dose question.